184 related articles for article (PubMed ID: 31696487)
21. Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi.
Sand M; Skrygan M; Sand D; Georgas D; Gambichler T; Hahn SA; Altmeyer P; Bechara FG
Cell Tissue Res; 2013 Jan; 351(1):85-98. PubMed ID: 23111773
[TBL] [Abstract][Full Text] [Related]
22. LncSNHG16 promotes proliferation and migration of osteosarcoma cells by targeting microRNA-146a-5p.
Zheng SN; Ge DW; Tang J; Yang J; Yan JW; Qiu JJ; Yin ZW; Ni Y; Zhao L; Chen X; Yang L
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(1):96-104. PubMed ID: 30657551
[TBL] [Abstract][Full Text] [Related]
23. miR-4262 promotes the proliferation of human cutaneous malignant melanoma cells through KLF6-mediated EGFR inactivation and p21 upregulation.
Zhang D; Li Z; Zhang Y; Tu C; Huo J; Liu Y
Oncol Rep; 2016 Dec; 36(6):3657-3663. PubMed ID: 27779691
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-124 inhibits proliferation and metastasis of esophageal cancer via negatively regulating NRP1.
Zang RK; Ma JB; Liang YC; Wang Y; Hu SL; Zhang Y; Dong W; Zhang W; Hu LK
Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4532-4541. PubMed ID: 30058693
[TBL] [Abstract][Full Text] [Related]
25. Connective tissue growth factor modulates oral squamous cell carcinoma invasion by activating a miR-504/FOXP1 signalling.
Yang MH; Lin BR; Chang CH; Chen ST; Lin SK; Kuo MY; Jeng YM; Kuo ML; Chang CC
Oncogene; 2012 May; 31(19):2401-11. PubMed ID: 21927029
[TBL] [Abstract][Full Text] [Related]
26. MiRNA-199 inhibits malignant progression of lung cancer through mediating RGS17.
Su WZ; Ren LF
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3390-3400. PubMed ID: 31081094
[TBL] [Abstract][Full Text] [Related]
27. miRNA-217 inhibits proliferation of hepatocellular carcinoma cells by regulating KLF5.
Gao W; Lu YX; Wang F; Sun J; Bian JX; Wu HY
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7874-7883. PubMed ID: 31599412
[TBL] [Abstract][Full Text] [Related]
28. GSTO1 regards as a meritorious regulator in cutaneous malignant melanoma cells.
Wang LK; Yue HL; Peng XJ; Zhang SJ
Mol Cell Probes; 2019 Dec; 48():101449. PubMed ID: 31525447
[TBL] [Abstract][Full Text] [Related]
29. LncRNA GIHCG promotes development of ovarian cancer by regulating microRNA-429.
Yao N; Yu L; Zhu B; Gan HY; Guo BQ
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8127-8134. PubMed ID: 30556850
[TBL] [Abstract][Full Text] [Related]
30. TRIM66 promotes malignant progression of hepatocellular carcinoma by inhibiting E-cadherin expression through the EMT pathway.
Zhang HG; Pan YW; Feng J; Zeng CT; Zhao XQ; Liang B; Zhang WW
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2003-2012. PubMed ID: 30915743
[TBL] [Abstract][Full Text] [Related]
31. microRNA-7-5p inhibits melanoma cell proliferation and metastasis by suppressing RelA/NF-κB.
Giles KM; Brown RA; Ganda C; Podgorny MJ; Candy PA; Wintle LC; Richardson KL; Kalinowski FC; Stuart LM; Epis MR; Haass NK; Herlyn M; Leedman PJ
Oncotarget; 2016 May; 7(22):31663-80. PubMed ID: 27203220
[TBL] [Abstract][Full Text] [Related]
32. miR-409 down-regulates Jak-Stat pathway to inhibit progression of liver cancer.
Zhang CS; Lin Y; Sun FB; Gao J; Han B; Li SJ
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(1):146-154. PubMed ID: 30657556
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-22 targets FMNL2 to inhibit melanoma progression via the regulation of the Wnt/β-catenin signaling pathway and epithelial-mesenchymal transition.
Shi L; Huo JW; Chen SS; Xue JX; Gao WY; Li XY; Song YH; Xu HT; Zhu XW; Chen K
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5332-5342. PubMed ID: 31298385
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-21 regulates the ERK/NF-κB signaling pathway to affect the proliferation, migration, and apoptosis of human melanoma A375 cells by targeting SPRY1, PDCD4, and PTEN.
Mao XH; Chen M; Wang Y; Cui PG; Liu SB; Xu ZY
Mol Carcinog; 2017 Mar; 56(3):886-894. PubMed ID: 27533779
[TBL] [Abstract][Full Text] [Related]
35. MiRNA-8073 targets ZnT1 to inhibit malignant progression of ovarian cancer.
Zhang L; Wang YH; Wang L
Eur Rev Med Pharmacol Sci; 2019 Jul; 23(14):6062-6069. PubMed ID: 31364107
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-330-5p promotes the development of osteosarcoma by regulating SPRY2.
Wei Q; Li QQ; Zhai XC; Qin L; Li HB; Meng R; Han XF
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8761-8770. PubMed ID: 31696462
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-155 and FOXP3 jointly inhibit the migration and invasion of colorectal cancer cells by regulating ZEB2 expression.
Yang LP; Lin Q; Mu XL
Eur Rev Med Pharmacol Sci; 2019 Jul; 23(14):6131-6138. PubMed ID: 31364113
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-200a promotes proliferation and invasion of ovarian cancer cells by targeting PTEN.
Jiang JH; Lv QY; Yi YX; Liao J; Wang XW; Zhang W
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6260-6267. PubMed ID: 30338796
[TBL] [Abstract][Full Text] [Related]
39. STAT3-induced upregulation of lncRNA SNHG17 predicts a poor prognosis of melanoma and promotes cell proliferation and metastasis through regulating PI3K-AKT pathway.
Gao H; Liu R; Sun X
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):8000-8010. PubMed ID: 31599425
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-424-5p inhibits the development of non-small cell LCa by binding to ITGB1.
Xu ZL; Zhang M; Chen SX; Qiu M; Zhang Q; Gao LP; Li JDX
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8921-8930. PubMed ID: 31696479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
